04
May

Sorrento Therapeutics, at work on a nanoparticle successor to the blockbuster cancer drug Abraxane, said its candidate is coming through in an ongoing Phase III trial. And while the biotech declined to get into specific details, the whiff of success sent its shares up more than 10% on Monday.

…read more

Source: Sorrento touts a vague victory for its next-gen Abraxane, and investors are buying

    

0 No comments